stockrow
Saturday 7 November 2026
Export SGMT’s income statement to Excel — free account
Sagimet Biosciences Inc.
SGMT Healthcare Biotechnology
Sagimet Biosciences Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.0 million.
- EPS
- +18.8%
- Free cash flow
- −22.0%
Quarter to June 2026, against a year earlier
9.82
0.70
+7.68%
Follow SGMT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 2 | — | — | — | — | 8 | 8 | 22 | +60.2% | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | — | — | 0.00 | +100.0 pt | ||||||
| EBT | — | — | — | (14) | (11) | (24) | (30) | (28) | (46) | (51) | (47) | +23.7% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (1,393.80) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | (14) | (11) | (24) | (30) | (28) | (46) | (51) | (47) | +23.7% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.67) | (0.53) | (1.14) | (165.20) | (2.66) | (1.45) | (1.58) | (1.28) | +15.4% | ||||||
| Cash flow | — | — | — | (0.49) | (0.49) | (1.02) | (132.67) | (2.27) | (1.35) | (1.41) | (0.79) | +19.1% | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (0.49) | (0.49) | (1.02) | (132.67) | (2.27) | (1.35) | (1.41) | (0.79) | +19.1% | ||||||
| Book value | — | — | — | 0.41 | 3.13 | 2.64 | (1,012.73) | 8.71 | 4.97 | 3.44 | 4.82 | +42.3% | ||||||
| Shares, m | — | — | — | 21 | 21 | 21 | 0 | 10 | 31 | 32 | 38 | +7.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | — | — | 0.00 | — | ||||||
| P/B | — | — | — | — | — | — | — | 0.61 | — | — | 2.04 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | 1.64 | — | — | (6.75) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (11) | (10) | (22) | (24) | (24) | (42) | (46) | (42) | +27.6% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | (11) | (10) | (22) | (24) | (24) | (42) | (46) | (42) | +27.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 9 | 67 | 55 | 28 | 91 | 148 | 111 | 239 | +52.8% | |||||
| Net debt | — | — | — | (10) | (68) | (56) | (32) | (95) | (151) | (113) | (240) | +50.2% | ||||||
| Shareholders’ equity | — | — | — | 9 | 67 | 56 | (187) | 91 | 156 | 111 | 256 | +52.5% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (28.38) | (38.19) | (66.26) | (42.97) | (35.46) | (36.89) | (23.49) | (36.9) pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (747.17) | 0.00 | (205.24) | 0.0 pt | ||||||
| ROE | — | — | — | 0.00 | 8.71 | 16.62 | 17.67 | 58.14 | (36.92) | (38.20) | (24.37) | (38.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 10 | 10 | 14 | 16 | — | +17.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.20 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2023 · latest quarter Sep 2023 · fundamentals updated 26 Oct 2026
Sagimet Biosciences Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences Inc. | $662.7M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −39.56% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AURA Aura Biosciences, Inc. | $657.5M | — (loss-making) | — | — | n/m | −56.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ACHV Achieve Life Sciences, Inc. | $656.0M | — (loss-making) | — | +54.44% (above 0%: growing) | n/m | −19.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SGMT Sagimet Biosciences Inc. | $641.5M | — (loss-making) | — (loss-making) | — | n/m | −21.95% (below 0%: shrinking) | 100.00% | 0.00% | |
| WVE WAVE Life Sciences Ltd. | $635.1M | — (loss-making) | — (loss-making) | +72.95% (above 0%: growing) | n/m | −33.94% (below 0%: shrinking) | 100.00% | (501.95%) | Compare |
| ZVRA Zevra Therapeutics, Inc. | $626.6M | 9.0× | 9.2× | +44.86% (above 0%: growing) | n/m | +106.77% (above 0%: growing) | 95.25% | 30.67% | Compare |
| FDMT 4D Molecular Therapeutics, Inc. | $621.5M | — (loss-making) | — (loss-making) | +25,106.67% (above 0%: growing) | n/m | −61.28% (below 0%: shrinking) | 100.00% | (2,037.16%) | Compare |
| DBVT DBV Technologies S.A. | $615.8M | — (loss-making) | — | −42.86% (below 0%: shrinking) | n/m | −64.93% (below 0%: shrinking) | 100.00% | (4,043.75%) | Compare |
| CADL Candel Therapeutics, Inc. | $615.2M | — (loss-making) | — (loss-making) | 0.00% | n/m | −93.35% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $630.8M | — | — | +44.86% | — | −47.91% | 47.63% | 0.00% |
Pay and ownership Proxy statement filed 21 April 2026
Ownership
Directors and executive officers, together
11.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement